Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 621 SEK -3.8% Market Closed
Market Cap: 36.6B SEK

EV/EBITDA
Enterprise Value to EBITDA

52.1
Current
66.3
Median
12.8
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
52.1
=
Enterprise Value
33.7B SEK
/
EBITDA
646m SEK
Market Cap EV/EBITDA
SE
Camurus AB
STO:CAMX
36.4B SEK 52.1
US
Eli Lilly and Co
NYSE:LLY
773.2B USD 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
374.6B USD 12.6
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 15.1
CH
Roche Holding AG
SIX:ROG
215.2B CHF 9.7
CH
Novartis AG
SIX:NOVN
190B CHF 10.6
UK
AstraZeneca PLC
LSE:AZN
169.1B GBP 131.2
US
Merck & Co Inc
NYSE:MRK
203.1B USD 8.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
139.4B USD 7.6
EBITDA Growth EV/EBITDA to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBITDA: 399.3
52.1
82%
0.6
US
Eli Lilly and Co
NYSE:LLY
37.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
30.5
2-Years Forward
EV/EBITDA
17.1
3-Years Forward
EV/EBITDA
11.5